Easywell Biomedicals Inc.
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and … Read more
Market Cap & Net Worth: Easywell Biomedicals Inc. (1799)
Easywell Biomedicals Inc. (TWO:1799) has a market capitalization of $123.61 Million (NT$4.09 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #20230 globally and #1042 in its home market, demonstrating a 16.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Easywell Biomedicals Inc.'s stock price NT$32.80 by its total outstanding shares 124690000 (124.69 Million).
Easywell Biomedicals Inc. Market Cap History: 2015 to 2026
Easywell Biomedicals Inc.'s market capitalization history from 2015 to 2026. Data shows change from $185.53 Million to $123.61 Million (-2.61% CAGR).
Easywell Biomedicals Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Easywell Biomedicals Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.57x
Easywell Biomedicals Inc.'s market cap is 0.57 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $52.61 Million | $359.96 Million | -$271.80 Million | 0.15x | N/A |
| 2020 | $92.39 Million | $267.65 Million | -$173.41 Million | 0.35x | N/A |
| 2021 | $84.67 Million | $197.28 Million | -$150.39 Million | 0.43x | N/A |
| 2022 | $59.83 Million | $178.90 Million | -$161.00 Million | 0.33x | N/A |
| 2023 | $153.95 Million | $271.63 Million | -$144.82 Million | 0.57x | N/A |
Competitor Companies of 1799 by Market Capitalization
Companies near Easywell Biomedicals Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Easywell Biomedicals Inc. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Easywell Biomedicals Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Easywell Biomedicals Inc.'s market cap moved from $185.53 Million to $ 123.61 Million, with a yearly change of -2.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$123.61 Million | -8.38% |
| 2025 | NT$134.92 Million | -44.32% |
| 2024 | NT$242.32 Million | +57.40% |
| 2023 | NT$153.95 Million | +157.32% |
| 2022 | NT$59.83 Million | -29.34% |
| 2021 | NT$84.67 Million | -8.36% |
| 2020 | NT$92.39 Million | +75.61% |
| 2019 | NT$52.61 Million | -10.18% |
| 2018 | NT$58.58 Million | -46.60% |
| 2017 | NT$109.70 Million | -0.48% |
| 2016 | NT$110.23 Million | -40.59% |
| 2015 | NT$185.53 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Easywell Biomedicals Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $123.61 Million USD |
| MoneyControl | $123.61 Million USD |
| MarketWatch | $123.61 Million USD |
| marketcap.company | $123.61 Million USD |
| Reuters | $123.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.